
Conformis CFMS
Quarterly report 2023-Q2
added 08-02-2023
Conformis Book Value 2011-2026 | CFMS
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Conformis
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 54.2 M | 101 M | 11.4 M | 16.3 M | 36.2 M | 46.5 M | 94.1 M | 141 M | 49.8 M | 69 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 141 M | 11.4 M | 61.9 M |
Quarterly Book Value Conformis
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 32 M | 44.6 M | 54.2 M | 61.2 M | 73.4 M | 86 M | 101 M | 115 M | 126 M | 87.3 M | 11.4 M | 11.4 M | 11.4 M | 11.4 M | 16.3 M | 16.3 M | 16.3 M | 16.3 M | 36.2 M | 36.2 M | 36.2 M | 36.2 M | 46.5 M | 46.5 M | 46.5 M | 46.5 M | 94.1 M | 94.1 M | 94.1 M | 94.1 M | 141 M | 141 M | 141 M | 141 M | 49.8 M | 49.8 M | 49.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 141 M | 11.4 M | 62.5 M |
Book Value of other stocks in the Medical devices industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Apollo Endosurgery
APEN
|
32.6 M | - | - | $ 475 M | ||
|
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
196 M | - | - | $ 1.77 B | ||
|
Axonics Modulation Technologies
AXNX
|
570 M | - | - | $ 3.31 B | ||
|
Acutus Medical
AFIB
|
-879 K | - | -26.83 % | $ 2.62 M | ||
|
Lianluo Smart Limited
LLIT
|
272 M | - | 24.59 % | $ 44.8 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
25.5 M | - | -5.86 % | $ 30.6 M | ||
|
Aziyo Biologics
AZYO
|
-38.6 M | - | 1.37 % | $ 20.5 M | ||
|
Apyx Medical Corporation
APYX
|
26.9 M | $ 3.92 | -1.51 % | $ 136 M | ||
|
Alphatec Holdings
ATEC
|
776 M | $ 13.47 | -3.09 % | $ 1.93 B | ||
|
Cognyte Software Ltd.
CGNT
|
217 M | $ 7.2 | -6.13 % | $ 517 M | ||
|
BIOLASE
BIOL
|
1.96 M | - | -13.19 % | $ 166 K | ||
|
Bio-Rad Laboratories
BIO
|
6.57 B | $ 293.69 | -2.09 % | $ 8.29 B | ||
|
Bruker Corporation
BRKR
|
1.82 B | $ 42.43 | 2.04 % | $ 6.32 K | ||
|
BioSig Technologies
BSGM
|
-1.42 M | - | 37.08 % | $ 85.7 M | ||
|
CONMED Corporation
CNMD
|
963 M | $ 42.33 | - | $ 1.31 B | ||
|
Boston Scientific Corporation
BSX
|
39.4 B | $ 73.47 | - | $ 108 B | ||
|
Abbott Laboratories
ABT
|
81.4 B | $ 113.59 | - | $ 198 B | ||
|
Cutera
CUTR
|
-172 M | - | -10.19 % | $ 1.99 M | ||
|
Cardiovascular Systems
CSII
|
249 M | - | 0.15 % | $ 844 M | ||
|
CryoLife, Inc.
CRY
|
58.1 M | - | -4.14 % | $ 702 M | ||
|
ClearPoint Neuro
CLPT
|
25.4 M | $ 13.37 | - | $ 361 M | ||
|
CHF Solutions, Inc.
CHFS
|
6.23 M | - | 1.15 % | $ 34.5 M | ||
|
EDAP TMS S.A.
EDAP
|
40.9 M | $ 4.9 | 6.52 % | $ 183 M | ||
|
Dynatronics Corporation
DYNT
|
3.26 M | - | 14.99 % | $ 929 K | ||
|
Soliton, Inc.
SOLY
|
243 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
2.61 B | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
229 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
30.4 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
52.2 M | - | - | $ 111 M | ||
|
Intersect ENT, Inc.
XENT
|
550 M | - | - | $ 955 M | ||
|
Eargo
EAR
|
101 M | - | - | $ 10.2 M | ||
|
Electromed
ELMD
|
43.2 M | $ 25.26 | - | $ 214 M | ||
|
InMode Ltd.
INMD
|
704 M | $ 14.24 | -2.6 % | $ 1.13 B | ||
|
IRadimed Corporation
IRMD
|
86.8 M | $ 103.08 | -1.97 % | $ 1.31 B | ||
|
Second Sight Medical Products
EYES
|
17.6 M | - | -0.97 % | $ 54.4 M | ||
|
Avinger
AVGR
|
-6.2 M | - | -20.74 % | $ 369 K | ||
|
FONAR Corporation
FONR
|
146 M | $ 18.58 | -0.69 % | $ 122 M | ||
|
GBS
GBS
|
2.81 M | - | -0.57 % | $ 7.12 M | ||
|
Integer Holdings Corporation
ITGR
|
1.62 B | $ 87.18 | 1.2 % | $ 2.93 B | ||
|
Globus Medical
GMED
|
4.18 B | $ 88.26 | -0.52 % | $ 12 B | ||
|
Pulmonx Corporation
LUNG
|
85.8 M | $ 1.45 | - | $ 56.7 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
1.55 B | $ 11.18 | 1.82 % | $ 861 M | ||
|
Establishment Labs Holdings
ESTA
|
53.1 M | $ 72.72 | 0.19 % | $ 2.05 B | ||
|
Medigus Ltd.
MDGS
|
17.6 M | - | 10.28 % | $ 55.5 M | ||
|
IRIDEX Corporation
IRIX
|
9.52 M | $ 1.43 | - | $ 23.1 M | ||
|
Invacare Corporation
IVC
|
771 M | - | - | $ 24.7 M | ||
|
Cytosorbents Corporation
CTSO
|
11.1 M | $ 0.62 | -7.43 % | $ 33.7 M | ||
|
Profound Medical Corp.
PROF
|
31.2 M | $ 6.44 | 1.26 % | $ 180 M |